首页 > 最新文献

Romanian Journal of Internal Medicine最新文献

英文 中文
Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients? 免疫治疗患者的淋巴结大小和过度进展之间是否存在关联?
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0025
Mohammad S Alkader, Rashed Z Altaha, Eslam H Jabali, Ola A Attieh, Ala' W Matalqa

Background: Hyperprogressive disease (HPD) can be described as an accelerated increase in the growth rate of tumors combined with rapid clinical deterioration observed in a subset of cancer patients undergoing immunotherapy, specifically with immune checkpoint inhibitors (ICIs). The reported incidence of HPD ranges from 5.9% to 43.1% in patients receiving ICIs. In this context, identifying reliable predictive risk factors for HPD is crucial as it may allow for earlier intervention and ultimately improve patient outcomes.

Methods: This study retrospectively analyzed ten metastatic renal cell carcinoma (mRCC) patients. The identification of HPD was based on the diagnostic criteria proposed by Ferrara R et al. This study aimed to investigate whether there is an association between LN size and HPD using a cutoff value of 3 cm for LN size. Given the limited sample size, Fisher's exact test was used to test this association. We conducted a Kaplan-Meier (KM) analysis to estimate the median overall survival (OS) of patients with HPD and compared it to those without HPD.

Results: Three patients (30%) developed HPD, while seven (70%) did not. Fisher's exact test revealed a statistically significant association between the HPD and LN size ≥ 3 cm (p=0.008). In the HPD group, the median OS was significantly shorter, with a median OS of 3 months, whereas in the non-HPD group, the median OS was not reached (P =0.001).

Conclusion: The present study found a significant association between LN size ≥ 3 cm in the pretreatment period and HPD development.

背景:超进行性疾病(HPD)可被描述为在接受免疫疗法(特别是免疫检查点抑制剂(ICIs))的癌症患者中观察到的肿瘤生长率加速增加,并伴有临床快速恶化。据报道,在接受ICIs的患者中,HPD的发病率在5.9%-43.1%之间。在这种情况下,确定HPD的可靠预测风险因素至关重要,因为它可以更早地进行干预,并最终改善患者的预后。方法:本研究回顾性分析了10例转移性肾细胞癌(mRCC)患者。HPD的鉴定基于Ferrara R等人提出的诊断标准。本研究旨在研究LN大小与HPD之间是否存在关联,LN大小的临界值为3cm。在样本量有限的情况下,使用Fisher精确检验来检验这种关联。我们进行了Kaplan-Meier(KM)分析来估计HPD患者的中位总生存期(OS),并将其与无HPD患者进行了比较。结果:3名患者(30%)出现HPD,7名患者(70%)没有。Fisher精确检验显示,HPD和LN大小≥3cm之间存在统计学显著相关性(p=0.008)。在HPD组中,中位OS明显更短,中位OS3个月,而在非HPD组,中位OS未达到(P=0.001)。结论:本研究发现,治疗前LN大小≥3cm与HPD的发生有显著相关性。
{"title":"Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?","authors":"Mohammad S Alkader, Rashed Z Altaha, Eslam H Jabali, Ola A Attieh, Ala' W Matalqa","doi":"10.2478/rjim-2023-0025","DOIUrl":"10.2478/rjim-2023-0025","url":null,"abstract":"<p><strong>Background: </strong>Hyperprogressive disease (HPD) can be described as an accelerated increase in the growth rate of tumors combined with rapid clinical deterioration observed in a subset of cancer patients undergoing immunotherapy, specifically with immune checkpoint inhibitors (ICIs). The reported incidence of HPD ranges from 5.9% to 43.1% in patients receiving ICIs. In this context, identifying reliable predictive risk factors for HPD is crucial as it may allow for earlier intervention and ultimately improve patient outcomes.</p><p><strong>Methods: </strong>This study retrospectively analyzed ten metastatic renal cell carcinoma (mRCC) patients. The identification of HPD was based on the diagnostic criteria proposed by Ferrara R <i>et al.</i> This study aimed to investigate whether there is an association between LN size and HPD using a cutoff value of 3 cm for LN size. Given the limited sample size, Fisher's exact test was used to test this association. We conducted a Kaplan-Meier (KM) analysis to estimate the median overall survival (OS) of patients with HPD and compared it to those without HPD.</p><p><strong>Results: </strong>Three patients (30%) developed HPD, while seven (70%) did not. Fisher's exact test revealed a statistically significant association between the HPD and LN size ≥ 3 cm (p=0.008). In the HPD group, the median OS was significantly shorter, with a median OS of 3 months, whereas in the non-HPD group, the median OS was not reached (P =0.001).</p><p><strong>Conclusion: </strong>The present study found a significant association between LN size ≥ 3 cm in the pretreatment period and HPD development.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50162773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The crucial role of gadolinium-enhanced MRI in a case of amaurosis fugax - a case report and literature review. 钆增强MRI在一例黑蒙中的重要作用——一例报告和文献综述。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0026
Maria Mirabela Manea, Dorin Dragoş, Ana-Maria Dobri, Maria Iuliana Ghenu, Iulia-Cosmina Stoican, Iulia-Ioana Enache, Sorin Tuta

Optic perineuritis is the inflammation of the optic nerve sheath. This affliction can lead to visual field impairment and other signs and symptoms related to the orbital space, such as pain, disc edema, ophthalmoplegia, proptosis. However, not all patients present with such suggestive symptoms, requiring a thorough assessment. We report the case of a young male admitted to our hospital for recurrent episodes of monocular blindness. Amaurosis fugax is a well-known presentation of transient ischemic attacks (TIA) and it was ruled out. Gadolinium-enhanced MRI revealed a typical aspect of optic perineuritis. It was mandatory to consider all possible causes of secondary optic perineuritis as they all represent serious clinical conditions, even if the idiopathic form is more frequent. The clinical and paraclinical evaluation of the patient excluded an underlying disease and primary optic perineuritis was diagnosed. Corticosteroid therapy is usually curative and a course of methylprednisolone was initiated for our patient with good outcome. However, response to treatment is not diagnostic as both primary and secondary optic perineuritis are normally responsive, hence thorough differential diagnosis is necessary.

视神经会阴炎是视神经鞘的炎症。这种痛苦会导致视野损伤和其他与眼眶相关的体征和症状,如疼痛、椎间盘水肿、眼肌麻痹、眼球突出。然而,并非所有患者都出现这种提示性症状,需要进行彻底评估。我们报告了一例年轻男性因单眼失明复发而入院的病例。黑蒙是短暂性脑缺血发作(TIA)的常见表现,已被排除在外。钆增强MRI显示了视神经会阴炎的一个典型方面。必须考虑继发性视神经会尿炎的所有可能原因,因为它们都代表着严重的临床状况,即使特发性会尿炎更常见。患者的临床和临床旁评估排除了潜在疾病,并诊断为原发性视神经会尿炎。皮质类固醇治疗通常是有疗效的,我们的患者开始了一个疗程的甲基强的松龙治疗,效果良好。然而,对治疗的反应并不是诊断性的,因为原发性和继发性视神经会尿炎都有正常反应,因此有必要进行彻底的鉴别诊断。
{"title":"The crucial role of gadolinium-enhanced MRI in a case of amaurosis fugax - a case report and literature review.","authors":"Maria Mirabela Manea, Dorin Dragoş, Ana-Maria Dobri, Maria Iuliana Ghenu, Iulia-Cosmina Stoican, Iulia-Ioana Enache, Sorin Tuta","doi":"10.2478/rjim-2023-0026","DOIUrl":"10.2478/rjim-2023-0026","url":null,"abstract":"<p><p>Optic perineuritis is the inflammation of the optic nerve sheath. This affliction can lead to visual field impairment and other signs and symptoms related to the orbital space, such as pain, disc edema, ophthalmoplegia, proptosis. However, not all patients present with such suggestive symptoms, requiring a thorough assessment. We report the case of a young male admitted to our hospital for recurrent episodes of monocular blindness. Amaurosis fugax is a well-known presentation of transient ischemic attacks (TIA) and it was ruled out. Gadolinium-enhanced MRI revealed a typical aspect of optic perineuritis. It was mandatory to consider all possible causes of secondary optic perineuritis as they all represent serious clinical conditions, even if the idiopathic form is more frequent. The clinical and paraclinical evaluation of the patient excluded an underlying disease and primary optic perineuritis was diagnosed. Corticosteroid therapy is usually curative and a course of methylprednisolone was initiated for our patient with good outcome. However, response to treatment is not diagnostic as both primary and secondary optic perineuritis are normally responsive, hence thorough differential diagnosis is necessary.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71426532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The hidden and complex relationship between dietary phosphorus and malnutrition in hemodialysis patients with chronic kidney disease. 慢性肾脏疾病血液透析患者膳食磷与营养不良之间隐藏而复杂的关系
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0029
Clonia Milla, Widodo, Teddy Heri Wardhana

Introduction: Chronic kidney disease (CKD) has always been a complicated global challenge, ranking as the 12th leading cause of death worldwide. Hemodialysis, being one of the most opted renal replacement therapies (RRTs) for patients with end-stage renal disease (ESRD), still possesses some limitations in preventing complications, such as malnutrition and mineral bone disease (CKD-MBD). While efforts have focused on controlling CKD-MBD parameters like calcium and phosphate, less attention has been given to dietary interventions. Moreover, the adoption of low-phosphorus diets for hemodialysis patients is very complex due to potential conflicts with the guideline-recommended high-protein dietary approach. This study sought to investigate the relationship between dietary phosphorus intake and nutritional status in CKD patients undergoing regular hemodialysis.

Method: This non-randomized cross-sectional study comprising 88 patients was conducted at the Hemodialysis Unit, RSUD Dr. Soetomo, Surabaya, East Java, using a three-day dietary record in March 2022. Relationships between variables were analyzed using Spearman and ANOVA tests.

Result: No significant positive association was found between dietary calcium with corrected calcium levels (p = 0.988; rs = -0.002) and between dietary phosphorus with plasma phosphate levels (p = 0.082; rs = 0.187). However, Spearman's analysis revealed a weak but positive correlation between dietary phosphorus and nutritional status (p = 0.022; rs = 0.215*).

Conclusion: Our study highlights a positive relationship between dietary phosphorus and nutritional status among hemodialysis patients, offering insights into potential strategies for optimizing patient care and outcomes.

慢性肾病(CKD)一直是一个复杂的全球性挑战,在全球死亡原因中排名第12位。血液透析作为终末期肾病(ESRD)患者最常用的肾脏替代疗法(RRTs)之一,在预防营养不良和矿物质骨病(CKD-MBD)等并发症方面仍存在一定局限性。虽然研究的重点是控制CKD-MBD参数,如钙和磷酸盐,但对饮食干预的关注较少。此外,血液透析患者采用低磷饮食是非常复杂的,因为它可能与指南推荐的高蛋白饮食方法相冲突。本研究旨在探讨定期进行血液透析的CKD患者膳食磷摄入量与营养状况之间的关系。方法:这项非随机横断面研究包括88名患者,于2022年3月在东爪哇泗水RSUD Dr. Soetomo血液透析部门进行,使用为期三天的饮食记录。采用Spearman检验和ANOVA检验分析变量之间的关系。结果:膳食钙与校正钙水平无显著正相关(p = 0.988;Rs = -0.002),且饲粮磷与血浆磷水平之间存在显著性差异(p = 0.082;Rs = 0.187)。然而,Spearman的分析显示,膳食磷与营养状况之间存在微弱的正相关关系(p = 0.022;Rs = 0.215*)。结论:我们的研究强调了血液透析患者膳食磷与营养状况之间的正相关关系,为优化患者护理和预后的潜在策略提供了见解。
{"title":"The hidden and complex relationship between dietary phosphorus and malnutrition in hemodialysis patients with chronic kidney disease.","authors":"Clonia Milla, Widodo, Teddy Heri Wardhana","doi":"10.2478/rjim-2023-0029","DOIUrl":"10.2478/rjim-2023-0029","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic kidney disease (CKD) has always been a complicated global challenge, ranking as the 12th leading cause of death worldwide. Hemodialysis, being one of the most opted renal replacement therapies (RRTs) for patients with end-stage renal disease (ESRD), still possesses some limitations in preventing complications, such as malnutrition and mineral bone disease (CKD-MBD). While efforts have focused on controlling CKD-MBD parameters like calcium and phosphate, less attention has been given to dietary interventions. Moreover, the adoption of low-phosphorus diets for hemodialysis patients is very complex due to potential conflicts with the guideline-recommended high-protein dietary approach. This study sought to investigate the relationship between dietary phosphorus intake and nutritional status in CKD patients undergoing regular hemodialysis.</p><p><strong>Method: </strong>This non-randomized cross-sectional study comprising 88 patients was conducted at the Hemodialysis Unit, RSUD Dr. Soetomo, Surabaya, East Java, using a three-day dietary record in March 2022. Relationships between variables were analyzed using Spearman and ANOVA tests.</p><p><strong>Result: </strong>No significant positive association was found between dietary calcium with corrected calcium levels (p = 0.988; r<sub>s</sub> = -0.002) and between dietary phosphorus with plasma phosphate levels (p = 0.082; r<sub>s</sub> = 0.187). However, Spearman's analysis revealed a weak but positive correlation between dietary phosphorus and nutritional status (p = 0.022; r<sub>s</sub> = 0.215*).</p><p><strong>Conclusion: </strong>Our study highlights a positive relationship between dietary phosphorus and nutritional status among hemodialysis patients, offering insights into potential strategies for optimizing patient care and outcomes.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central retinal vein occlusion : an uncommon complication in sarcoidosis. 视网膜中央静脉阻塞:结节病的一种罕见并发症。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0024
Imen Chabchoub, Chifa Damak, Marwa Bouhamed, Mouna Rekik, Cyrine Abid, Faten Frikha, Sonda Kammoun, Yoldez Ben Jemaa, Sameh Marzouk, Zouhir Bahloul

Sarcoidosis is a multi-system granulomatosis of unknown etiology, defined by the presence of epithelioid and gigantocellular granulomas, without caseous necrosis. Ocular sarcoidosis manifests mainly as bilateral granulomatous anterior uveitis. Occlusion of the central retinal vein in sarcoidosis is a rare manifestation, which is the particularity of our observation. We report the case of a patient presenting with unilateral central retinal vein occlusion associated with granulomatous anterior uveitis on the same side. Systemic manifestations and further investigations led to the diagnosis of sarcoidosis.

结节病是一种病因不明的多系统肉芽肿病,其特征是存在上皮样和巨细胞肉芽肿,无干酪样坏死。眼部结节病主要表现为双侧肉芽肿性前葡萄膜炎。结节病视网膜中央静脉闭塞是一种罕见的表现,这是我们观察的特殊性。我们报告了一例患者出现单侧视网膜中央静脉阻塞并伴有同侧肉芽肿性前葡萄膜炎。系统表现和进一步的调查导致结节病的诊断。
{"title":"Central retinal vein occlusion : an uncommon complication in sarcoidosis.","authors":"Imen Chabchoub, Chifa Damak, Marwa Bouhamed, Mouna Rekik, Cyrine Abid, Faten Frikha, Sonda Kammoun, Yoldez Ben Jemaa, Sameh Marzouk, Zouhir Bahloul","doi":"10.2478/rjim-2023-0024","DOIUrl":"10.2478/rjim-2023-0024","url":null,"abstract":"<p><p>Sarcoidosis is a multi-system granulomatosis of unknown etiology, defined by the presence of epithelioid and gigantocellular granulomas, without caseous necrosis. Ocular sarcoidosis manifests mainly as bilateral granulomatous anterior uveitis. Occlusion of the central retinal vein in sarcoidosis is a rare manifestation, which is the particularity of our observation. We report the case of a patient presenting with unilateral central retinal vein occlusion associated with granulomatous anterior uveitis on the same side. Systemic manifestations and further investigations led to the diagnosis of sarcoidosis.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49681757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune dysfunction in patients with end stage kidney disease; Immunosenescence - Review. 终末期肾病患者的免疫功能障碍免疫衰老-综述。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0030
Viorica Ileana Bumbea, Horia Bumbea, Ana Maria Vladareanu

The body's defense against environmental factors is realized by physical barriers and cells of both the innate and adaptive immune systems. Patients with end stage kidney disease (ESKD), especially those treated by hemodialysis, have changes in both the function and the number or percent of different leukocyte subsets. Changes were described at the level of monocytes and lymphocyte subsets, which are associated with immunodeficiencies and pro-inflammatory status correlated with degenerative changes and increased cardiovascular risk. These abnormalities have been compared over the past years with alterations appearing as a result ageing. Also, similitudes regarding immunosenescence observed in ESKD patients, in combination with chronic inflammation, are described as the so-called "inflammaging syndrome".

机体对环境因素的防御是通过先天免疫系统和适应性免疫系统的物理屏障和细胞来实现的。终末期肾病(ESKD)患者,特别是那些接受血液透析治疗的患者,在功能和不同白细胞亚群的数量或百分比上都有变化。在单核细胞和淋巴细胞亚群水平上描述了变化,这些变化与免疫缺陷和与退行性变化和心血管风险增加相关的促炎状态有关。在过去的几年里,这些异常与衰老导致的变化进行了比较。此外,在ESKD患者中观察到的与慢性炎症有关的免疫衰老的相似之处被描述为所谓的“炎症综合征”。
{"title":"Immune dysfunction in patients with end stage kidney disease; Immunosenescence - Review.","authors":"Viorica Ileana Bumbea, Horia Bumbea, Ana Maria Vladareanu","doi":"10.2478/rjim-2023-0030","DOIUrl":"10.2478/rjim-2023-0030","url":null,"abstract":"<p><p>The body's defense against environmental factors is realized by physical barriers and cells of both the innate and adaptive immune systems. Patients with end stage kidney disease (ESKD), especially those treated by hemodialysis, have changes in both the function and the number or percent of different leukocyte subsets. Changes were described at the level of monocytes and lymphocyte subsets, which are associated with immunodeficiencies and pro-inflammatory status correlated with degenerative changes and increased cardiovascular risk. These abnormalities have been compared over the past years with alterations appearing as a result ageing. Also, similitudes regarding immunosenescence observed in ESKD patients, in combination with chronic inflammation, are described as the so-called \"inflammaging syndrome\".</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia. 人类免疫缺陷病毒阴性Castleman病患者的临床特征和结果:突尼斯一项单一医学中心研究。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0028
Imen Chabchoub, Raida Ben Salah, Rim Kallel, Mouna Snoussi, Feten Frikha, Sameh Marzouk, Tahya Sellami Boudawara, Zouhir Bahloul

Introduction: Castleman's disease (CD), known as angiofollicular lymph node hyperplasia, is an uncommon condition. The two most common histological subtypes are hyaline vascular and plasma cell. We performed a retrospective analysis to define the clinic-pathological features and survival of CD, which is quite rare focusing on the particularities of our series with a review of the recent literature.

Methods: This is a retrospective study conducted in the department of internal medicine of Hedi Chaker hospital in Sfax, Tunisia over 25 years. The disease was histologically confirmed in all patients. For each file, we collected a set of data by filling in a pre-designed form.

Results: 18 patients were included. There were 8 men and 10 women with a mean age of 42.8 years. CD was monocentric in 5 cases (28%) and multicentric in 13 cases (72%). Clinically, peripheral adenopathy was present in 77.7% of patients and deep adenopathy in 72.2%. Systemic signs were found in 13 patients, including general condition (4.4%), fever (16.6%), serositis (27.7%), and skin involvement (33.3%). A biological inflammatory syndrome accompanied the clinical picture in 66% of patients. Abnormalities in the blood count were found in 12 cases (66%), with anemia in 11 cases, thrombocytosis in 3 cases, and hypereosinophilia in 3 cases. Cutaneous Kaposi's sarcoma was associated with Castleman's disease in 2 cases, Hodgkin's lymphoma, angioimmunoblastic T-cell lymphoma, and lymph node T-cell lymphoma were found in 1 case respectively. 3 of the patients had associated connective tissue diseases such as Sjögren's syndrome in 2 cases and rheumatoid arthritis in 1 case. HHV8 serology was positive in 1 case with a multicentric plasma cell form. Histologically, the plasma cell form represented 50% of cases, hyaline-vascular (39% of cases), and mixed (11% of cases). Therapeutically, high-dose corticosteroid therapy was initiated in 13 cases. As a second-line treatment, MOPP chemotherapy was used in 1 case due to transformation into Hodgkin's lymphoma, and biotherapy (rituximab) was used in 2 cases in the multicentric form. Surgical removal of superficial adenopathy was performed in 2 patients with monocentric CD.

Conclusion: : Castleman's disease (CD) is a non-malignant lymphoproliferation of localized or multicentric form with a wide and heterogeneous clinical spectrum. Diagnosis can be difficult due to the lack of clinical and radiological specificity. Management depends on the clinical form involving surgical and/or medical management.

引言:Castleman病(CD),即血管滤泡性淋巴结增生,是一种罕见的疾病。两种最常见的组织学亚型是透明血管和浆细胞。我们进行了回顾性分析,以确定CD的临床病理特征和生存率,这是非常罕见的,重点关注我们系列的特殊性,并回顾了最近的文献。方法:这是一项在突尼斯斯法克斯Hedi Chaker医院内科进行的25年回顾性研究。所有患者均经组织学证实患有该病。对于每个文件,我们通过填写预先设计的表格收集了一组数据。结果:包括18名患者。男8例,女10例,平均年龄42.8岁。CD单中心5例(28%),多中心13例(72%)。临床上,77.7%的患者出现外周性腺病,72.2%的患者出现深部腺病。13名患者出现全身症状,包括全身症状(4.4%)、发烧(16.6%)、浆膜炎(27.7%)和皮肤受累(33.3%)。66%的患者伴有生物炎症综合征。血细胞计数异常12例(66%),贫血11例,血小板增多3例,嗜酸性粒细胞增多3例。皮肤Kaposi肉瘤伴Castleman病2例,霍奇金淋巴瘤、血管免疫母细胞性T细胞淋巴瘤和淋巴结T细胞淋巴瘤各1例。其中3例患者有相关结缔组织疾病,如2例干燥综合征和1例类风湿性关节炎。1例多中心浆细胞型HHV8血清学阳性。组织学上,浆细胞型占50%,透明血管型(39%),混合型(11%)。在治疗上,13例患者开始了高剂量皮质类固醇治疗。作为二线治疗,1例因转化为霍奇金淋巴瘤而使用MOPP化疗,2例多中心形式使用生物治疗(利妥昔单抗)。2例单中心CD患者进行了浅表腺病的手术切除。结论:Castleman病(CD)是一种局限性或多中心的非恶性淋巴增生病,临床谱广泛且异质。由于缺乏临床和放射学的特异性,诊断可能很困难。管理取决于涉及外科和/或医疗管理的临床形式。
{"title":"Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.","authors":"Imen Chabchoub, Raida Ben Salah, Rim Kallel, Mouna Snoussi, Feten Frikha, Sameh Marzouk, Tahya Sellami Boudawara, Zouhir Bahloul","doi":"10.2478/rjim-2023-0028","DOIUrl":"10.2478/rjim-2023-0028","url":null,"abstract":"<p><strong>Introduction: </strong>Castleman's disease (CD), known as angiofollicular lymph node hyperplasia, is an uncommon condition. The two most common histological subtypes are hyaline vascular and plasma cell. We performed a retrospective analysis to define the clinic-pathological features and survival of CD, which is quite rare focusing on the particularities of our series with a review of the recent literature.</p><p><strong>Methods: </strong>This is a retrospective study conducted in the department of internal medicine of Hedi Chaker hospital in Sfax, Tunisia over 25 years. The disease was histologically confirmed in all patients. For each file, we collected a set of data by filling in a pre-designed form.</p><p><strong>Results: </strong>18 patients were included. There were 8 men and 10 women with a mean age of 42.8 years. CD was monocentric in 5 cases (28%) and multicentric in 13 cases (72%). Clinically, peripheral adenopathy was present in 77.7% of patients and deep adenopathy in 72.2%. Systemic signs were found in 13 patients, including general condition (4.4%), fever (16.6%), serositis (27.7%), and skin involvement (33.3%). A biological inflammatory syndrome accompanied the clinical picture in 66% of patients. Abnormalities in the blood count were found in 12 cases (66%), with anemia in 11 cases, thrombocytosis in 3 cases, and hypereosinophilia in 3 cases. Cutaneous Kaposi's sarcoma was associated with Castleman's disease in 2 cases, Hodgkin's lymphoma, angioimmunoblastic T-cell lymphoma, and lymph node T-cell lymphoma were found in 1 case respectively. 3 of the patients had associated connective tissue diseases such as Sjögren's syndrome in 2 cases and rheumatoid arthritis in 1 case. HHV8 serology was positive in 1 case with a multicentric plasma cell form. Histologically, the plasma cell form represented 50% of cases, hyaline-vascular (39% of cases), and mixed (11% of cases). Therapeutically, high-dose corticosteroid therapy was initiated in 13 cases. As a second-line treatment, MOPP chemotherapy was used in 1 case due to transformation into Hodgkin's lymphoma, and biotherapy (rituximab) was used in 2 cases in the multicentric form. Surgical removal of superficial adenopathy was performed in 2 patients with monocentric CD.</p><p><strong>Conclusion: </strong>: Castleman's disease (CD) is a non-malignant lymphoproliferation of localized or multicentric form with a wide and heterogeneous clinical spectrum. Diagnosis can be difficult due to the lack of clinical and radiological specificity. Management depends on the clinical form involving surgical and/or medical management.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72210621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Massive primary pulmonary artery rhabomyosarcoma: A case report. 大块原发性肺动脉横纹肌肉瘤1例报告。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0032
Farid Rashidi, Eissa Bilehjani, Seyed Ali Mousavi-Aghdas, Rezayat Parvizi

Background: Pulmonary artery sarcomas (PAS) are rare tumours causing an insidiously progressive obstruction of the pulmonary circulation. The clinical presentation is often indistinguishable from chronic thromboembolic pulmonary hypertension (CTEPH). However, the atypical appearance of a heterogeneous filling defect in CT pulmonary angiography (CTPA) should prompt further investigation.

Case presentation: A previously healthy young man presented with massive haemoptysis, acute respiratory distress, and progressive exertional dyspnea since the year before. Echocardiography demonstrated severe right ventricular dysfunction and highly probable pulmonary hypertension. CTPA revealed an extensive filling defect with an appearance concerning PAS. Due to syncopal episodes at rest, the patient underwent urgent pulmonary artery endarterectomy (PEA). A massive tree-like tumour was excised as a result. Post-operatively, reperfusion injury and refractory pulmonary oedema mandated extracorporeal membrane oxygenation (ECMO). Unfortunately, ECMO was complicated with massive haemolysis and acute kidney injury. The patient succumbed to multi-organ failure. Through tissue analysis established a diagnosis of embryonal rhabdomyosarcoma.

Discussion: Unfortunately, the patient had not reached out for his worsening dyspnea. PASs should not be mistaken for a thrombus and anticoagulation should be avoided. The urgent condition precluded biopsy and tissue diagnosis. Similarly, neoadjuvant chemotherapy was not feasible. Post-operatively, reperfusion injury and pulmonary oedema ensued, which mandated ECMO. This complication should be anticipated preoperatively. There is a need for more data on PASs to establish a consensus for management.

背景:肺动脉肉瘤(PAS)是一种罕见的肿瘤,引起肺循环的隐性进行性阻塞。临床表现往往难以区分慢性血栓栓塞性肺动脉高压(CTEPH)。然而,CT肺血管造影(CTPA)中不典型的异质充盈缺陷的表现应引起进一步的研究。病例介绍:一名健康的年轻男性,自一年前以来出现大量咯血,急性呼吸窘迫和进行性用力呼吸困难。超声心动图显示严重的右心室功能障碍和极可能的肺动脉高压。CTPA显示广泛的充盈缺陷,其外观与PAS有关。由于休息时晕厥发作,患者接受了紧急肺动脉内膜切除术(PEA)。结果切除了一个巨大的树状肿瘤。术后,再灌注损伤和难治性肺水肿需要体外膜氧合(ECMO)。不幸的是,ECMO并发大量溶血和急性肾损伤。病人死于多器官衰竭。通过组织分析确定胚胎性横纹肌肉瘤的诊断。讨论:不幸的是,病人并没有及时处理他日益恶化的呼吸困难。PASs不应被误认为是血栓,应避免抗凝。由于病情紧急,无法进行活检和组织诊断。同样,新辅助化疗也不可行。术后出现再灌注损伤和肺水肿,需进行ECMO。这种并发症应在术前预料到。需要更多关于PASs的数据,以便为管理建立共识。
{"title":"Massive primary pulmonary artery rhabomyosarcoma: A case report.","authors":"Farid Rashidi, Eissa Bilehjani, Seyed Ali Mousavi-Aghdas, Rezayat Parvizi","doi":"10.2478/rjim-2023-0032","DOIUrl":"10.2478/rjim-2023-0032","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary artery sarcomas (PAS) are rare tumours causing an insidiously progressive obstruction of the pulmonary circulation. The clinical presentation is often indistinguishable from chronic thromboembolic pulmonary hypertension (CTEPH). However, the atypical appearance of a heterogeneous filling defect in CT pulmonary angiography (CTPA) should prompt further investigation.</p><p><strong>Case presentation: </strong>A previously healthy young man presented with massive haemoptysis, acute respiratory distress, and progressive exertional dyspnea since the year before. Echocardiography demonstrated severe right ventricular dysfunction and highly probable pulmonary hypertension. CTPA revealed an extensive filling defect with an appearance concerning PAS. Due to syncopal episodes at rest, the patient underwent urgent pulmonary artery endarterectomy (PEA). A massive tree-like tumour was excised as a result. Post-operatively, reperfusion injury and refractory pulmonary oedema mandated extracorporeal membrane oxygenation (ECMO). Unfortunately, ECMO was complicated with massive haemolysis and acute kidney injury. The patient succumbed to multi-organ failure. Through tissue analysis established a diagnosis of embryonal rhabdomyosarcoma.</p><p><strong>Discussion: </strong>Unfortunately, the patient had not reached out for his worsening dyspnea. PASs should not be mistaken for a thrombus and anticoagulation should be avoided. The urgent condition precluded biopsy and tissue diagnosis. Similarly, neoadjuvant chemotherapy was not feasible. Post-operatively, reperfusion injury and pulmonary oedema ensued, which mandated ECMO. This complication should be anticipated preoperatively. There is a need for more data on PASs to establish a consensus for management.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carpal tunnel syndrome and nerve conduction studies in fibromyalgia patients. 纤维肌痛患者腕管综合征和神经传导的研究。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0031
Gülseren Demir Karakiliç, Güven Arslan

Introduction: The aim of this study is to evaluate ENMG results of female patients with Fibromyalgia Syndrome (FMS) with a preliminary diagnosis of carpal tunnel syndrome (CTS) and to examine whether there are differences in ENMG results compared to control group.

Material and methods: Ethical approval was obtained for this study on 30.12.2022 with number E. Kurul-2022-20/32 and recorded retrospectively between January 2021 and January 2023. 201 female patients who were diagnosed with FMS in Physical Therapy and Rehabilitation polyclinic and who were requested to have ENMG testing with a preliminary diagnosis of CTS were included in study as patient group. 201 patients were ıncluded as control group.

Results: While the number of patients with right CTS was 39 (25.49%) in the FMS group, the number of patients with right CTS was 38 (24.20%) in control group. While the number of patients with left CTS was 34 (25%) in the FMS group, number of patients with left CTS in the control group was 36 (24.65%). When we analyzed a total of 592 ENMG results in our study, we found a high normal ENMG rate of 75%.

Conclusion: We found that there was no difference between the FMS and the control group in terms of compatibility between the pre-diagnosis and electroneurophysiological diagnosis in the ENMG results requested with the pre-diagnosis of CTS in our study. The ENMG examination should be requested for right patient in right indication, by first evaluating the patient well.

简介:本研究旨在评价初步诊断为腕管综合征(CTS)的女性纤维肌痛综合征(FMS)患者的ENMG结果,并探讨其与对照组的ENMG结果是否存在差异。材料和方法:本研究于2022年12月30日获得伦理批准,编号E. Kurul-2022-20/32,回顾性记录时间为2021年1月至2023年1月。选取201例在物理治疗与康复综合诊所确诊为FMS的女性患者,并要求进行初步诊断为CTS的ENMG检测作为患者组。201例患者ıncluded为对照组。结果:FMS组右侧CTS 39例(25.49%),对照组右侧CTS 38例(24.20%)。FMS组左侧CTS 34例(25%),对照组左侧CTS 36例(24.65%)。当我们对592例ENMG结果进行分析时,我们发现ENMG正常率高达75%。结论:我们发现FMS与对照组在CTS预诊断所要求的ENMG结果的预诊断与神经电生理诊断的相容性方面没有差异。应首先对患者进行评估,并在正确的适应症下对患者进行ENMG检查。
{"title":"Carpal tunnel syndrome and nerve conduction studies in fibromyalgia patients.","authors":"Gülseren Demir Karakiliç, Güven Arslan","doi":"10.2478/rjim-2023-0031","DOIUrl":"10.2478/rjim-2023-0031","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study is to evaluate ENMG results of female patients with Fibromyalgia Syndrome (FMS) with a preliminary diagnosis of carpal tunnel syndrome (CTS) and to examine whether there are differences in ENMG results compared to control group.</p><p><strong>Material and methods: </strong>Ethical approval was obtained for this study on 30.12.2022 with number E. Kurul-2022-20/32 and recorded retrospectively between January 2021 and January 2023. 201 female patients who were diagnosed with FMS in Physical Therapy and Rehabilitation polyclinic and who were requested to have ENMG testing with a preliminary diagnosis of CTS were included in study as patient group. 201 patients were ıncluded as control group.</p><p><strong>Results: </strong>While the number of patients with right CTS was 39 (25.49%) in the FMS group, the number of patients with right CTS was 38 (24.20%) in control group. While the number of patients with left CTS was 34 (25%) in the FMS group, number of patients with left CTS in the control group was 36 (24.65%). When we analyzed a total of 592 ENMG results in our study, we found a high normal ENMG rate of 75%.</p><p><strong>Conclusion: </strong>We found that there was no difference between the FMS and the control group in terms of compatibility between the pre-diagnosis and electroneurophysiological diagnosis in the ENMG results requested with the pre-diagnosis of CTS in our study. The ENMG examination should be requested for right patient in right indication, by first evaluating the patient well.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shedding light on weight loss: A narrative review of medications for treating obesity. 揭示减肥:治疗肥胖药物的叙述性综述。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0023
Haritha Darapaneni, Samridhi Lakhanpal, Hiren Chhayani, Kinna Parikh, Meet Patel, Vasu Gupta, Fnu Anamika, Ripudaman Munjal, Rohit Jain

Obesity and overweight are the major risk factors for numerous chronic diseases, including cardiovascular diseases such as heart disease and stroke, which are the leading causes of death worldwide. The prevalence of obesity has dramatically risen in both developed and developing countries, making it a significant public health concern and a global crisis. Despite lifestyle modifications being the first-line treatment, the high risk of relapse has led to a growing interest in non-invasive pharmacotherapeutic interventions to achieve and maintain weight loss and reverse the growth of the obesity epidemic. Cardiovascular diseases and cancer account for the highest mortality rates among other comorbidities associated with obesity and overweight. Excess and abnormally deposited adipose tissue secretes various inflammatory mediators, leading to cardiovascular diseases and cancers. Weight loss of 5-10% significantly reduces cardiometabolic risk. Medications currently approved in the USA for long-term management of obesity are orlistat, naltrexone, bupropion, phentermine/topiramate, and Glucagon Like Peptide-1 (GLP-1) agonists such as liraglutide and semaglutide. The benefit-to-risk of medications, comorbidities, and individual responses should guide the treatment decisions. The article provides a comprehensive overview and discussion of several weight loss medications used previously and currently, including their efficacy, mechanisms of action, and side effects.

肥胖和超重是许多慢性疾病的主要风险因素,包括心脏病和中风等心血管疾病,它们是全球死亡的主要原因。发达国家和发展中国家的肥胖率都急剧上升,使其成为一个重大的公共卫生问题和全球危机。尽管改变生活方式是一线治疗方法,但复发的高风险导致人们对非侵入性药物治疗干预措施越来越感兴趣,以实现和保持体重减轻,扭转肥胖流行的增长。在与肥胖和超重相关的其他合并症中,心血管疾病和癌症的死亡率最高。过量和异常沉积的脂肪组织会分泌各种炎症介质,导致心血管疾病和癌症。体重减轻5-10%可显著降低心脏代谢风险。美国目前批准用于长期治疗肥胖的药物有奥利司他、纳曲酮、安非他酮、苯妥明/托吡酯和胰高血糖素样肽-1(GLP-1)激动剂,如利拉鲁肽和西格鲁肽。药物风险、合并症和个体反应的益处应指导治疗决策。这篇文章对以前和现在使用的几种减肥药物进行了全面的概述和讨论,包括它们的疗效、作用机制和副作用。
{"title":"Shedding light on weight loss: A narrative review of medications for treating obesity.","authors":"Haritha Darapaneni, Samridhi Lakhanpal, Hiren Chhayani, Kinna Parikh, Meet Patel, Vasu Gupta, Fnu Anamika, Ripudaman Munjal, Rohit Jain","doi":"10.2478/rjim-2023-0023","DOIUrl":"10.2478/rjim-2023-0023","url":null,"abstract":"<p><p>Obesity and overweight are the major risk factors for numerous chronic diseases, including cardiovascular diseases such as heart disease and stroke, which are the leading causes of death worldwide. The prevalence of obesity has dramatically risen in both developed and developing countries, making it a significant public health concern and a global crisis. Despite lifestyle modifications being the first-line treatment, the high risk of relapse has led to a growing interest in non-invasive pharmacotherapeutic interventions to achieve and maintain weight loss and reverse the growth of the obesity epidemic. Cardiovascular diseases and cancer account for the highest mortality rates among other comorbidities associated with obesity and overweight. Excess and abnormally deposited adipose tissue secretes various inflammatory mediators, leading to cardiovascular diseases and cancers. Weight loss of 5-10% significantly reduces cardiometabolic risk. Medications currently approved in the USA for long-term management of obesity are orlistat, naltrexone, bupropion, phentermine/topiramate, and Glucagon Like Peptide-1 (GLP-1) agonists such as liraglutide and semaglutide. The benefit-to-risk of medications, comorbidities, and individual responses should guide the treatment decisions. The article provides a comprehensive overview and discussion of several weight loss medications used previously and currently, including their efficacy, mechanisms of action, and side effects.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MLPA in the initial genetic screening of patients with acute myeloid leukemia. MLPA在急性髓系白血病患者初步基因筛查中的应用。
IF 1.9 Q2 Medicine Pub Date : 2024-03-23 Print Date: 2024-03-01 DOI: 10.2478/rjim-2023-0027
Dinnar Yahya, Mari Hachmeriyan, Tsanka Ruseva, Trifon Chervenkov, Ilina Micheva

Introduction: This study aimed to assess the effectiveness of multiplex ligase-dependent probe amplification (MLPA) in the initial genetic screening of patients with acute myeloid leukemia (AML) since current risk stratification and clinical management depend on molecular-genetic markers.

Methods: We performed a prospective case-control study on newly diagnosed patients from the Clinical hematology clinic of UMHAT "St. Marina", Varna, for the period 02.2022 - 02.2023. MLPA - a semiquantitative PCR-based method, was implemented with probes for 40 AML/myelodysplastic syndrome-typical genetic changes. We compared these findings with a parallelly carried out cytogenetic analysis, part of the routine diagnostic process.

Results: We assessed 61 patients - 29 females and 32 males, median age of 61 years for females and 65 for males (min-max 20-89). 34 (56%) of all showed pathological results, while the rest 27 (44%) did not. Of the 34, 22 (65%) had a single gene variant in genes NPM1, DNMT3A, FLT3, and IDH2, isolated or in combination. 18 (53%) of the same 34 also had copy number aberration (CNA) in chromosomes 4, 5, 6, 7, 11, 14, 17, and 21. The latter were either isolated or in combination with other findings. 8 of the 18 cases also underwent cytogenetic analysis, with concordance between the two methods in 4.

Conclusion: MLPA is an informative method for initial genetic assessment in addition to cytogenetic analysis. Still, more patients are needed to draw finite conclusions on its eligibility for routine use. Given the significant percentage of normal results - 44%, simultaneous evaluation of more genetic markers, included in current guidelines, is reasonable.

引言:本研究旨在评估多重连接酶依赖性探针扩增(MLPA)在急性髓系白血病(AML)患者初始基因筛查中的有效性,因为目前的风险分层和临床管理依赖于分子遗传标记。方法:我们对2022年2月至2023年2月期间来自瓦尔纳UMHAT“St.Marina”临床血液学诊所的新诊断患者进行了前瞻性病例对照研究。MLPA是一种基于半定量PCR的方法,用探针检测40例AML/骨髓增生异常综合征的典型遗传变化。我们将这些发现与平行进行的细胞遗传学分析进行了比较,细胞遗传学分析是常规诊断过程的一部分。结果:我们评估了61名患者——29名女性和32名男性,女性的中位年龄为61岁,男性为65岁(最小-最大20-89岁)。34例(56%)有病理结果,其余27例(44%)无病理结果。在34个基因中,22个(65%)在NPM1、DNMT3A、FLT3和IDH2基因中存在单一基因变体,无论是分离的还是组合的。在同一34条染色体中,有18条(53%)在第4、5、6、7、11、14、17和21号染色体上也有拷贝数畸变(CNA)。后者要么是孤立的,要么与其他发现相结合。18例中有8例也进行了细胞遗传学分析,两种方法在4例中一致。结论:MLPA是一种除细胞遗传学分析外的初步遗传评估方法。尽管如此,仍需要更多的患者对其是否适合常规使用得出有限的结论。考虑到正常结果的显著百分比(44%),同时评估当前指南中包含的更多遗传标记是合理的。
{"title":"MLPA in the initial genetic screening of patients with acute myeloid leukemia.","authors":"Dinnar Yahya, Mari Hachmeriyan, Tsanka Ruseva, Trifon Chervenkov, Ilina Micheva","doi":"10.2478/rjim-2023-0027","DOIUrl":"10.2478/rjim-2023-0027","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess the effectiveness of multiplex ligase-dependent probe amplification (MLPA) in the initial genetic screening of patients with acute myeloid leukemia (AML) since current risk stratification and clinical management depend on molecular-genetic markers.</p><p><strong>Methods: </strong>We performed a prospective case-control study on newly diagnosed patients from the Clinical hematology clinic of UMHAT \"St. Marina\", Varna, for the period 02.2022 - 02.2023. MLPA - a semiquantitative PCR-based method, was implemented with probes for 40 AML/myelodysplastic syndrome-typical genetic changes. We compared these findings with a parallelly carried out cytogenetic analysis, part of the routine diagnostic process.</p><p><strong>Results: </strong>We assessed 61 patients - 29 females and 32 males, median age of 61 years for females and 65 for males (min-max 20-89). 34 (56%) of all showed pathological results, while the rest 27 (44%) did not. Of the 34, 22 (65%) had a single gene variant in genes NPM1, DNMT3A, FLT3, and IDH2, isolated or in combination. 18 (53%) of the same 34 also had copy number aberration (CNA) in chromosomes 4, 5, 6, 7, 11, 14, 17, and 21. The latter were either isolated or in combination with other findings. 8 of the 18 cases also underwent cytogenetic analysis, with concordance between the two methods in 4.</p><p><strong>Conclusion: </strong>MLPA is an informative method for initial genetic assessment in addition to cytogenetic analysis. Still, more patients are needed to draw finite conclusions on its eligibility for routine use. Given the significant percentage of normal results - 44%, simultaneous evaluation of more genetic markers, included in current guidelines, is reasonable.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72210622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Romanian Journal of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1